-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 LUnrox2EobzNwnGbQaRKW3GowtFA5fdZukxCO+4ulRiUX2COKQnCjVrVNIUfuRhg
 lCOqS8Cvgzl5JBCaEV1OvQ==

<SEC-DOCUMENT>0000950123-05-002767.txt : 20050308
<SEC-HEADER>0000950123-05-002767.hdr.sgml : 20050308
<ACCEPTANCE-DATETIME>20050308163357
ACCESSION NUMBER:		0000950123-05-002767
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20050308
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20050308
DATE AS OF CHANGE:		20050308

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PHIBRO ANIMAL HEALTH CORP
		CENTRAL INDEX KEY:			0001069899
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				131840497
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-64641
		FILM NUMBER:		05667149

	BUSINESS ADDRESS:	
		STREET 1:		ONE PARKER PLZ
		CITY:			FORT LEE
		STATE:			NJ
		ZIP:			07024
		BUSINESS PHONE:		2019446020

	MAIL ADDRESS:	
		STREET 1:		ONE PARKET PLZ
		CITY:			FORT LEE
		STATE:			NJ
		ZIP:			07024

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPP BROTHERS CHEMICALS INC
		DATE OF NAME CHANGE:	19980908
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>y06594e8vk.txt
<DESCRIPTION>PHIBRO ANIMAL HEALTH CORPORATION
<TEXT>
<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 Current Report


     Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

         Date of report (date of earliest event reported): March 8, 2005

                        Phibro Animal Health Corporation
             (Exact name of registrant as specified in its charter)

         New York                      333-64641               13-1840497
- ----------------------------          ------------           -------------------
(State or other jurisdiction          (Commission             (IRS Employer
     of incorporation)                File Number)           Identification No.)

                               65 CHALLENGER ROAD
                        RIDGEFIELD PARK, NEW JERSEY 07660
               (Address of principal executive offices) (Zip Code)

                                 (201) 329-7300
              (Registrant's telephone number, including area code)

   Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))


<PAGE>

Item 7.01 Regulation FD Disclosure

   Phibro Animal Health Corporation (the "Company"), and its indirect wholly
owned subsidiary, Philipp Brothers Netherlands III B.V., issued a press release
on March 8, 2005, announcing the extension until 5:00 p.m., New York City time,
on March 9, 2005, of their offer to issue units consisting of their 13% Senior
Secured Notes due 2007 registered under the Securities Act of 1933 in exchange
for unregistered units consisting of their 13% Senior Secured Notes due 2007, as
described in their Prospectus dated March 2, 2005, amending their Prospectus
dated February 4, 2005. The terms of the new securities are substantially
identical to those of the outstanding securities, except that the transfer
restrictions and registration rights applicable to the outstanding securities do
not apply to the securities to be issued in the exchange offer, which have been
registered under the Securities Act of 1933. Approximately 99% of the
outstanding securities had been tendered as of the time the press release was
issued. A copy of the press release is attached as Exhibit 99.1 to this Report.

   HSBC Bank USA, National Association is the Exchange Agent for the exchange
offer.

   The information being furnished under Item 7.01 of this Report shall not be
considered "filed" for purposes of the Securities and Exchange Act of 1934.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

Exhibit No.        Description
- -----------        -----------
99.1               Press Release issued March 8, 2005


                                       2

<PAGE>


                                   SIGNATURES

   Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                         PHIBRO ANIMAL HEALTH CORPORATION


Dated: March 8, 2005                     By:     /s/ Richard G. Johnson
                                            ---------------------------------
                                                     Richard G. Johnson
                                                     Chief Financial Officer


<PAGE>


                                  Exhibit Index

Exhibit No.        Description
- -----------        -----------
99.1               Press release dated March 8, 2005


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>y06594exv99w1.txt
<DESCRIPTION>PRESS RELEASE
<TEXT>
<PAGE>

                                                                   Exhibit 99.1

                                  Press Release
                                  -------------

For additional information contact: Richard G. Johnson, Chief Financial Officer
- - 201 329-7300.

Phibro Animal Health Corporation and Philipp Brothers Netherlands III BV extend
expiration date of exchange offer for units consisting of their 13% Senior
Secured Notes due 2007 until 5:00 p.m., New York City time, on March 9, 2005.

March 8, 2005: Ridgefield Park, New Jersey

   Phibro Animal Health Corporation (the "Company") and its wholly owned
indirect subsidiary, Philipp Brothers Netherlands III B.V., announced today the
extension until 5:00 p.m., New York City time, on March 9, 2005, of their offer
to issue units consisting of their 13% Senior Secured Notes due 2007 registered
under the Securities Act of 1933 in exchange for unregistered units consisting
of their 13% Senior Secured Notes due 2007, as described in their Prospectus
dated March 2, 2005, amending their Prospectus dated February 4, 2005. The terms
of the new securities are substantially identical to those of the outstanding
securities, except that the transfer restrictions and registration rights
applicable to the outstanding securities do not apply to the securities to be
issued in the exchange offer, which have been registered under the Securities
Act of 1933. Approximately 99% of the outstanding securities have been tendered.

   HSBC Bank USA, National Association is the Exchange Agent for the exchange
offer.

Company Description

   The Company is a leading diversified global manufacturer and marketer of a
broad range of animal health and nutrition products, specifically medicated feed
additives ("MFAs") and nutritional feed additives, which the Company sells
throughout the world predominantly to the poultry, swine and cattle markets.
MFAs are used preventively and therapeutically in animal feed to produce healthy
livestock. The Company is also a specialty chemicals manufacturer and marketer,
serving numerous markets

Philipp Brothers Netherlands III B.V.

   Philipp Brothers Netherlands III B.V., the Dutch issuer, is an indirect
wholly-owned subsidiary of the Company and is incorporated under the laws of the
Netherlands as a private company with limited liability. The Dutch issuer is a
holding company formed to finance the operations of PAH Belgium, which owns and
operates the Company's Rixensart, Belgium plant. Such plant uses fermentation
processes to produce the active ingredients semduramicin and virginiamycin and
conducts all of the Company's fermentation development activities.

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
